New treatment for relapsing remitting MS recommended for PBS listing
26 June 2025
The Pharmaceutical Benefits Advisory Committee has recommended ublituximab (Briumvi®) be listed on the PBS for treating relapsing remitting MS.
The Pharmaceutical Benefits Advisory Committee has recommended ublituximab (Briumvi®) be listed on the PBS for treating relapsing remitting MS.
CEO Rohan Greenland responds to the latest NDIS pricing decision, warning it threatens access to essential therapies and places additional pressure on MS Member Organisations already going above and beyond.
Is targeting EBV the key to treating MS? Two new clinical trials are testing antiviral therapies to slow progression and reduce fatigue.
MS Australia is reviewing its 21-year-old research program to ensure it continues delivering the greatest impact for people living with MS.
Nurses play a critical role in strengthening economies, improving health systems, and ensuring better outcomes for communities worldwide. MS Australia has released a report outlining what we can do to better support our MS nursing workforce now and into the future.Â
MS Australia is extremely disappointed with last week’s release of the 2024-25 NDIS Pricing Review.Â
Launched on World MS Day, Living Well with MS is a practical guide to support lifestyle choices in people living with MS, backed by science and lived experience.
CEO Rohan Greenland shares an enormous thank you to everyone who took part in or supported this year’s iconic May 50K, and outlines MS Australia’s advocacy priorities in the post-election landscape.
Researchers studying identical twins and laboratory models have found that certain gut bacteria may be linked to MS development.